IP Library Granted Patent US 7,125,689
Granted Patent B2
US 7,125,689 · App. 10/300,215 · Granted Oct 24, 2006

Method for rendering streptokinase less immunogenic to a human

Assignee: Biovation Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,125,689
App. No.
10/300,215
Granted
Oct 24, 2006
Kind
B2
Abstract

Protein, or parts of proteins, may be rendered non-immunogenic, or less immunogenic, to a given species by identifying in their amino acid sequences one or more potential epitopes for T-cells of the given species and modifying the amino acid sequence to eliminate at least one of the T-cell epitopes. This eliminates or reduces the immunogenicity of the protein when exposed to the immune system of the given species. Monoclonal antibodies and other immunoglobulin-like molecules can particularly benefit from being de-immunised in this way: for example, mouse-derived immunoglobulins can be de-immunised for human therapeutic use.

Claims (4)

1. A method of rendering streptokinase non-immunogenic or less immunogenic when exposed to the immune system of a human, the method comprising the steps of:

(a) identifying a first set of potential T-cell epitope sequences within the amino acid residue sequence of streptokinase (SEQ ID NO: 252) by (i) analysing said amino acid sequence for the presence of MHC class II binding motifs, and (ii) comparing the MHC class II binding motifs in the streptokinase amino acid residue sequence with human MHC binding motifs available from an MHC database;

(b) comparing the first set of potential T-cell epitope sequences identified in step (a) with human immunoglobulin variable region germ line amino acid residue sequences available from a human germ-line sequence database to identify a subset of potential T-cell epitopes within the streptokinase amino acid residue sequence that are not present in human immunoglobulin variable region germ-line sequences; and

(c) preparing a de-immunized streptokinase polypeptide having the amino acid residue sequence of SEQ ID NO: 252 but including at least one amino acid residue substitution that eliminates from the streptokinase amino acid residue sequence at least one epitope sequence from the subset identified in step (b), wherein the de-immunized streptokinase polypeptide has the amino acid residue sequence of SEQ ID NO: 253.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 14, 2007
From: BIOVATION LIMITED
To: MERCK PATENT GMBH
Reel/Frame 020254/0909 →
Priority Claims (4)
GB 9710480.6 · May 21, 1997 · national
GB 9716197.0 · Jul 31, 1997 · national
GB 9725270.4 · Nov 28, 1997 · national
GB 9807751.4 · Apr 14, 1998 · national
Continuity (4)
Continuation 0943813600 · Nov 10, 1999
Continuation PCTGB980147300 · May 21, 1998
Provisional Application 6006723500 · Dec 2, 1997
Related Publication 20030153043A1 · Aug 14, 2003